NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$9.79

-0.26 (-2.59%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.50
▼
$10.00
50-Day Range: $9.79
▼
$13.05
52-Week Range: $6.18
▼
$27.96

Volume: 2.12 million shs
Average Volume: 2.08 million shs
Market Capitalization: $1.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.80

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 143.1% Upside
$23.80 Price Target
Short Interest: Healthy
13.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.53) to ($2.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

741st out of 1,080 stocks

Biological Products, Except Diagnostic Industry

123rd out of 172 stocks

3.4

Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.80, Iovance Biotherapeutics has a forecasted upside of 143.1% from its current price of $9.79.
Amount of Analyst Coverage
Iovance Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
13.73% of the float of Iovance Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Iovance Biotherapeutics has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Iovance Biotherapeutics has recently decreased by 5.35%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Iovance Biotherapeutics has received a 67.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Iovance Biotherapeutics is -1.23.

0.0

News and Social Media Coverage

Search Interest
Only 12 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Iovance Biotherapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.53) to ($2.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

September 14, 2022 | americanbankingnews.com

Iovance Biotherapeutics' (IOVA) Buy Rating Reaffirmed at JMP Securities

September 10, 2022 | seekingalpha.com

IOVA Iovance Biotherapeutics, Inc.

September 6, 2022 | finance.yahoo.com

Iovance Biotherapeutics to Present Posters at ESMO 2022

September 5, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from Analysts

September 5, 2022 | msn.com

As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field

August 25, 2022 | finance.yahoo.com

Biomedical technician training program launches to support Philadelphia's growing life sciences sector

August 6, 2022 | seekingalpha.com

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

August 5, 2022 | markets.businessinsider.com

Expert Ratings for Iovance Biotherapeutics

August 5, 2022 | nasdaq.com

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

August 5, 2022 | seekingalpha.com

Iovance Biotherapeutics, Inc. (IOVA) CEO Fred Vogt on Q2 2022 Results - Earnings Call Transcript

July 12, 2022 | seekingalpha.com

Iovance: TIL Cell Therapy Set To Prove Itself

July 1, 2022 | markets.businessinsider.com

7 Analysts Have This to Say About Iovance Biotherapeutics

June 13, 2022 | finance.yahoo.com

Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

June 6, 2022 | finance.yahoo.com

Down More Than 40%: Insiders Call a Bottom in These 2 Stocks

June 3, 2022 | seekingalpha.com

Iovance climbs over 15% after multiple insider purchases

May 30, 2022 | nasdaq.com

Iovance Biotherapeutics Now the Least Expensive vs. Bitcoin This Year

May 27, 2022 | barrons.com

Iovance Stock Tumbles on Cancer Data. Analysts Say the Selloff Went Too Far.

May 27, 2022 | finance.yahoo.com

Why Iovance Biotherapeutics Was Halved Today

May 27, 2022 | finance.yahoo.com

Iovance (IOVA) Down After Announcing Data From Melanoma Study

May 26, 2022 | seekingalpha.com

Iovance slips as objective response rate reaches 29% for melanoma candidate

May 26, 2022 | finance.yahoo.com

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

May 26, 2022 | finance.yahoo.com

Iovance's stock slides 40% after sharing data about its melanoma therapy

May 6, 2022 | finance.yahoo.com

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

April 27, 2022 | finance.yahoo.com

Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting

April 20, 2022 | seekingalpha.com

Iovance: Onward To Approval

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings: 8/04/2022
Today: 9/24/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IOVA
CUSIP: N/A
CIK: 1425205
Web: www.iovance.com
Phone: (650) 260-7120
Fax: N/A
Employees: 319
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $23.80
High Stock Price Forecast: $43.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +143.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-342,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -64.21%
Return on Assets: -51.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.72
Quick Ratio: 6.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.96 per share
Price / Book: 2.47

Miscellaneous

Outstanding Shares: 157,170,000
Free Float: 145,223,000
Market Cap: $1.54 billion
Optionable: Optionable
Beta: 0.50

Key Executives

Dr. Frederick G. Vogt Esq. (Age 48)
J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
Comp: $752.81k

Mr. Jean-Marc Bellemin M.B.A. (Age 50)
Chief Financial Officer & Principal Accounting Officer
Comp: $623.6k

Dr. Igor P. Bilinsky (Age 49)
Chief Operating Officer
Comp: $577.35k

Dr. Friedrich Graf Finckenstein M.D. (Age 55)
Chief Medical Officer
Comp: $649.13k

Ms. Sara Pellegrino
VP of Investor Relations & PR

Ms. Tracy Winton
Sr. VP of HR

Mr. Howard B. Johnson M.B.A. (Age 62)
Chief Bus. Officer

Mr. James Ziegler M.B.A.
Exec. VP of Commercial

Mr. Madan Jagasia
Exec. VP of Medical Affairs

Dr. Raj K. Puri M.D.
Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.
What is Iovance Biotherapeutics' stock price forecast for 2022?: 10 Wall Street research analysts have issued 1-year price targets for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $13.00 to $43.00. On average, they anticipate the company's stock price to reach $23.80 in the next year. This suggests a possible upside of 143.1% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.
How have IOVA shares performed in 2022?: Iovance Biotherapeutics' stock was trading at $19.09 at the beginning of 2022. Since then, IOVA stock has decreased by 48.7% and is now trading at $9.79.
View the best growth stocks for 2022 here.
When is Iovance Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our IOVA earnings forecast.
How were Iovance Biotherapeutics' earnings last quarter?: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.03. During the same period in the prior year, the business earned ($0.53) EPS.
What other stocks do shareholders of Iovance Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?: Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
Who are Iovance Biotherapeutics' major shareholders?: Iovance Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (7.49%), Franklin Resources Inc. (3.29%), Price T Rowe Associates Inc. MD (2.77%), Pictet Asset Management SA (2.31%), ARK Investment Management LLC (1.87%) and Sumitomo Mitsui Trust Holdings Inc. (1.78%). Insiders that own company stock include Frederick G Vogt and Merrill A Mcpeak.
View institutional ownership trends.
How do I buy shares of Iovance Biotherapeutics?: Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Iovance Biotherapeutics' stock price today?: One share of IOVA stock can currently be purchased for approximately $9.79.
How much money does Iovance Biotherapeutics make?: Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.54 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.
How many employees does Iovance Biotherapeutics have?: The company employs 319 workers across the globe.
How can I contact Iovance Biotherapeutics?: Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

Iovance Biotherapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month